// App-Quantinova.ai

3867 : The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Rachael F. Grace

Principal Investigators

  • Kristen E. Stevenson

  • Donna S. Neuberg

  • Stephen E. Sallan

  • Lewis B. Silverman

  • Daniel J. DeAngelo

  • Jean M. Connors

Medical Centers

  • Harvard University/Dana Farber Cancer Institute, Boston, MA

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Department of Pediatric Oncology, Boston Childrens Hospital, Dana-Farber Cancer Institute, Harvard Medical School, HHMI, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Thrombocytopenia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Fibrinogen

Drug/Treatment

  • Heparin

  • Fondaparinux sodium

  • Asparaginase

  • dalteparin Subcutaneous

  • Enoxaparin

  • Enoxaparin sodium

  • Fibrinogen (IV)

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved